Novacyt is developing a biogenic PCR test to better identify COVID-19, as well as a respiratory panel that can distinguish it from influenza A, B and respiratory syncytial viruses. The company is going to launch these products on the market in September 2020. In addition, the company carries out its own assessment of the effectiveness of the partner developed test for the definition of antibodies IgG, which is scheduled for release on the market in the 4th quarter of 2020.
Novacyt is developing a biogenic PCR test to better identify COVID-19, as well as a respiratory panel that can distinguish it from influenza A, B and respiratory syncytial viruses. The company is going to launch these products on the market in September 2020. In addition, the company carries out its own assessment of the effectiveness of the partner developed test for the definition of antibodies IgG, which is scheduled for release on the market in the 4th quarter of 2020. 
English (US) 